Towa Pharmaceutical Co., Ltd.
Cite as: Japan IR Index, Towa Pharmaceutical Co., Ltd. (4553), methodology GNT-BDS v1.1.1, reviewed 2026-10-20.
Findings and sources as of the review date shown. The company’s English disclosure may have changed since.
Where to start
Chosen from this company's lowest answers, easiest first. A quick fix uses material the company already has; a translation fix is usually met by translating a Japanese document (our note says whether this company has one). Questions that need a budget or a board decision are left out. Suggestions drawn from the research, separate from the scores.
F6 Multi-year financial data file (Excel or CSV) downloadable in English 0/5 Quick fix
Post the financial figures the company already publishes as an Excel or CSV file with English labels.
G6 Shareholder vote results disclosed in English 0/5 Quick fix
Publish the vote counts from the Japanese extraordinary report in English.
S3 English equity-story or investment-highlights page 3/5 Translation
Put the investment case, with figures, on one English page or section.
G1 Corporate governance report available in English 3/5 Translation
Publish the corporate governance report filed with TSE in English.
English disclosure assessment
All 34 questions reviewed by the editor against the public documents; this is not an independent audit. 1 answer corrected after re-checks (research errors) on 23 Oct 2026. These are changes to our record, not to the company’s disclosure. Changes to this record →
Compared with peers
| Peer group | Median | This company |
|---|---|---|
| Same sector (Pharmaceutical) | 75.4 | 6 of 12 |
| Same size band (¥100–500bn) | 77.1 | 23 of 50 |
Compared with the companies covered here, not the whole market. Sector is the TSE 33-sector classification; market cap is from the TSE English-disclosure survey, Aug 2026; it only sets the size band, plays no part in the score, and is refreshed once a quarter. Ties share the higher rank.
Out of 100.
Of the 34 questions reviewed, 29 scored 3 or more and 3 found no qualifying English materials within the stated review scope. Read each score with its source and scope below.
Findings by question
F1Quarterly and full-year results summaries (tanshin) published in English5/5
English 'Consolidated Financial Results' (Japanese GAAP) for every quarter on the English Supplementary Materials / Summary page and on TDnet at the same minute as the Japanese (Q1 FY2026 6 Aug 2026 15:30; FY2025 14 May 2026 15:30; Q3 13 Feb 2026; H1 10 Nov 2025). Each is a whole translation: Q1 FY2026 14 pp against 15 Japanese, FY2025 22 pp against 19, with the qualitative section and the segment note. Every period, complete, on the Japanese cycle, so 5, as complete as the Miura and Fuji Electric examples. Source document →
F2English results summary is a full translation, not an excerpt5/5
Q1 FY2026 tanshin read against the Japanese 2027年3月期 第1四半期決算短信 (15 pp). The English (14 pp) has the same table of contents item for item: 1. Overview of operating results and financial position ((1) results with Domestic and Overseas segment discussion, (2) financial position, (3) forecast explanation); 2. statements (balance sheet, income and comprehensive income, cash flows) and notes (segment information, significant changes in shareholders' equity, going concern). Whole translation, so 5, matching the Zeon and DMG Mori examples. Source document →
F3Financial statements including notes available in English5/5
The latest English tanshin (Q1 FY2026, 6 Aug 2026) carries the quarterly balance sheet, income and comprehensive income, cash flows and the notes, segment note included (reportable segments Domestic and Overseas with sales, intersegment sales, segment profit and the reconciliation). The FY2025 English tanshin (22 pp) has the full-year statements and notes. Full statements and notes for the latest period, so 5. Source document →
F4Annual securities report available in English in any form0/5
Looked through the English IR menu (Greetings, Mid-term Business Plan, Management Risks, Disclosure Policy, Financial Highlight, Supplementary Materials / Summary of Consolidated Financial Results, Integrated Report, Ordinary General Meeting of Shareholders, IR Calendar) and the English Information list back to 2025: no annual securities report in English under any name. The Japanese library has the 有価証券報告書.
F5Segment revenue and profit disclosed in English, consistent definitions5/5
Two reportable segments, Domestic (Towa, Sunsho) and Overseas (Towa INT, Europe and US). Every English tanshin gives net sales, intersegment sales and segment profit per segment with the reconciliation (Q1 FY2026: Domestic sales ¥55,981m, profit ¥7,013m; Overseas ¥15,612m and ¥5m), and states the basis: segment profit is operating profit before goodwill amortisation. The deck adds plans per business (Towa Pharmaceutical etc., Sunsho, Towa INT). So 5, as the Hirata and Yaskawa examples. Source document →
F6Multi-year financial data file (Excel or CSV) downloadable in English0/5
The English Financial Highlight page is an HTML table of four years (FY2022-FY2025: net sales, OP, ordinary profit, net profit, net assets, total assets, BPS, EPS, equity ratio, DPS) with charts; there is no Excel or CSV link on it or anywhere in the English IR menu. HTML table only, so no downloadable data file.
F7Guidance disclosed in English with the basis explained5/5
The English FY2025 deck (14 May 2026, 46 pp) sets out the FY2026 plan consolidated and per business (Towa Pharmaceutical etc. sales and segment profit ¥31.5bn; Sunsho ¥2.0bn; Towa INT sales ¥60.0bn with Europe ¥38.6bn and US ¥21.4bn), the assumed rates (EUR ¥177.00, USD ¥154.00) and the reasons (production-capacity increase, sales mix, new launches in European BtoC and the US). The 11 May 2026 English notice explains the impairment and the forecast revision; the Q1 English tanshin says the forecast is unchanged. FX, segment forecasts and market view, revisions explained, so 5, comparable to the Resonac and Misumi examples. Source document →
F8English financial disclosure current to the latest Japanese filing period5/5
English results for the three months to 30 June 2026 were filed on TDnet at 15:30 on 6 August 2026, the same minute as the Japanese, and are on the English IR page. Same period. Source document →
S1Medium-term management plan in English with numerical targets4/5
6th Medium-term Business Plan 2024-2026 'PROACTIVE III' in English: the one-page formulation notice the same day as the Japanese (10 Jun 2024), the 47-page plan (the same 47 pages as the Japanese, which was created 6 Jun 2024) with an English file created 17 Jul 2024, and the 15 May 2025 notice revising the targets, the same day as the Japanese. Targets: consolidated sales ¥300bn and non-consolidated ¥200bn in the final year, cumulative OP ¥68bn raised to ¥80bn, ROIC 6%+ (7%+ before goodwill), R&D ¥55bn and capex ¥60bn cumulative. Complete, but the plan deck came about five weeks after the Japanese, so 4. Source document →
S2IR presentations published in English5/5
The English Supplementary Materials page mirrors the Japanese 決算資料 item for item: the deck every quarter at the same page count (Q1 FY2026 27 pp against 27; FY2025 46 against 46), on TDnet at the same minute as the Japanese, and the 'Briefing Script and Q&A Summary' for every briefing that has a Japanese スクリプト・質疑応答要旨 (Q1 FY2026 15 pp, FY2025 27, Q3 17, Q2 16; neither language has one for Q1 FY2025). Also the English script and Q&A of the Tanabe Pharma Factory acquisition briefing. The scripts arrive later (S5, R1). So 5, the same set as the Shimadzu example. Source document →
S3English equity-story or investment-highlights page3/5
No investment-highlights page in English. The IR 'Greetings' page, addressed to shareholders and investors, describes Towa's three strategies (value-added formulations such as RACTAB, fair-price sales, the Towa sales system) in prose, with no figures. Corporate Data and History are generic. Strengths described rather than framed and quantified for an investor, so 3. Source document →
S4Growth drivers identified and quantified in English4/5
The English PROACTIVE III plan names the drivers: production capacity to 17.5 billion tablets a year (third solid formulation building at Yamagata), stable supply, overseas growth through Towa INT, and new health businesses through Sunsho. Some are quantified (capacity, the ¥300bn sales target, cumulative capex and R&D), and the FY2025 deck gives tablet volumes (15.71 and 16.43 billion) and plans by business. But the plan has no contribution of each driver to the target and no market sizes or shares. Named, some quantified, so 4. Source document →
S5Results-briefing transcripts or Q&A published in English4/5
An English 'Briefing Script and Q&A Summary' exists for every briefing the Japanese side publishes one for, always later: Q1 FY2026 Japanese created 19 Aug 2026, English listed 2 Sep; FY2025 29 May against 17 Jun; Q3 6 Mar against 18 Mar; H1 17 Dec 2025 against 26 Dec. Every period, one to three weeks late, so 4. Source document →
S6Integrated or annual report available in English4/5
TOWA PHARMACEUTICAL INTEGRATED REPORT 2025 in English, 62 pp, on TDnet on 23 Dec 2025; the Japanese 東和薬品統合報告書2025 has the same 62 pages (created 21 Oct 2025). It covers FY2024 (April 2024 to March 2025). No 2026 edition in either language yet. Complete, one edition behind for a March year-end, so 4. Source document →
S7Progress against the previous plan, including misses, explained in English4/5
The English PROACTIVE III deck opens with '5th Medium-term Business Plan (2021-2023) - Review': achievements by policy (p.4), then four pages of financial targets against results, each marked 'Achieved' or 'Not achieved in final year' (non-consolidated sales ¥149.2bn not achieved, consolidated sales ¥227.9bn achieved, cumulative OP, R&D and capex achieved). The miss is not explained. Reconciliation without the explanation, so 4; the Espec and Kayaku examples give the reasons. Source document →
G1Corporate governance report available in English3/5
No Corporate Governance Report in English. The English Corporate Governance page is a narrative (concept of governance, risk-management structure) written for the site. The Japanese CG Report was updated on 13 Oct 2026, 29 Jun 2026 and 13 Apr 2026 on TDnet with no English version. A site narrative in place of the filing, so 3. Source document →
G2Director biographies in English with tenure, expertise and independence5/5
The English notice of the 70th AGM gives every candidate for both proposals (six directors, four Audit and Supervisory Committee members: the whole board) a dated career summary (e.g. Yoshida: director since Dec 1983, President since June 1996 'to present'), shares held, reasons for nomination, independence designation, and the outside directors' tenure in words (e.g. 'eleven (11) years'). Tenure, expertise and independence for every director, so 5. Source document →
G3Board skills matrix published in English5/5
The English AGM notice (p.25) shows the composition of the board and the skills of each director if Proposals 4 and 5 are approved: the current matrix in English, as the Riken Keiki example. Source document →
G4Executive remuneration structure and its performance linkage explained in English3/5
The English Integrated Report 2025 (pp.49-50) gives the compensation policy and structure (basic compensation, bonuses based on individual performance, mid- to long-term performance-based stock compensation, introduced 2019) and the FY2024 amounts by type (directors ¥195m: basic ¥120m, bonus ¥15m, performance-based monetary ¥52m, non-monetary ¥6m; A&SC members ¥42m). It names no KPI for the performance-based pay and no weights. Amounts without KPIs, so 3. Source document →
G5AGM notice in English with sufficient lead time to vote4/5
Notice of the 70th Ordinary General Meeting in English (25 pp), on TDnet at 08:00 on 29 May 2026, the same minute as the Japanese, for a meeting on 24 June: 26 days. It carries the reference documents for all five proposals in full, including the Class A preferred share issue to DBJ and the articles amendment, with every candidate's profile. It explains voting via the internet or in writing, with the deadline (17:40 on 23 June). The '(in Japanese)' label attaches to the materials website only. The Japanese notice is 46 pp because it includes the business report. Re-checked 23 Oct 2026 (G5 voting-site sweep, after the independent audit): the company's shareholder pages name Mitsubishi UFJ Trust and Banking as share registrar, whose voting website (evote.tr.mufg.jp) is in Japanese only, with no English option, as for ESPEC (6859) and Nitto Boseki (3110). Every proposal in English, but a Japanese-only voting route, so 4. Source document →
G6Shareholder vote results disclosed in English0/5
The English Ordinary General Meeting page lists notices only (60th to 70th). No notice of resolutions and no voting results in English, and none on the English Information list or on TDnet in English. The Japanese meeting page has 決議ご通知 and 臨時報告書 (the vote counts).
G7Cross-shareholdings in English with reduction schedule and rationale2/5
The English Integrated Report 2025 (p.50, 'Cross-shareholdings') gives only the policy: holdings at a business partner's request when they contribute to corporate value, a yearly board review, the voting policy, and not hindering sales. No number of holdings, no amount, no target and no progress. The governance-report boilerplate policy only, so 2. Source document →
O1English IR section reachable within two clicks of the English homepage5/5
On the English homepage (towayakuhin.co.jp/english/) 'IR' in the header navigation links straight to the IR top (/english/ir/), and the homepage has IR and Mid-term Business Plan tiles. One click, so 5. Source document →
O2English document links resolve to English documents5/5
Sampled 16 English links across types and years: tanshin 2022, 2024 (H1, FY), Q3 FY2025, Q1 FY2026; decks 2015, 2022, H1 FY2025; script H1 FY2025; AGM notices 63rd, 69th; Integrated Reports 2022 and 2024; MTP 2018-2020 and the 2024 notice; the 2025 MTP revision. All English (CJK only in the slogan and some chart labels). So 5. Source document →
O3English IR archive free of dead links5/5
In the same sample of 16 links (2015-2026), every one resolved to a live PDF (1 to 62 pp). No dead links, so 5. Source document →
O4English IR pages render without blank JavaScript failures5/5
Rendered the English homepage, IR top, Mid-term Business Plan, Financial Highlight (table and charts), Supplementary Materials (back-number accordions to FY2006), Integrated Report, Ordinary General Meeting, Disclosure Policy, Greetings, IR Calendar, Corporate Governance, Board Members, Information back numbers and Contact. All render their content, so 5. Source document →
O5Single page listing all English IR documents by date and type4/5
The English 'Information' list (/english/info/2026/, year tabs back to 2016) is one dated list of the English items: tanshin, decks, scripts, AGM notice, timely disclosures, integrated report and IR-calendar updates. It is untyped, and some documents never appear on it (the FY2025 and Q3 scripts, the MTP deck). One dated list, untyped, not every item, so 4. Source document →
O6English archive genuinely populated, not an unverifiable shell5/5
Decks every quarter back to FY2010 and half-year results to FY2006, English tanshin every quarter since FY2021, AGM notices from the 60th to the 70th, integrated reports 2021-2025, MTPs back to 2008-2010, and the Information list back to 2016. Several years across types, so 5. Source document →
O7Named English IR contact published4/5
'CONTACT' in the header of every English IR page opens a one-screen contact page listing 'IR Inquiries ir@towayakuhin.co.jp' separately from PR inquiries: a dedicated IR address, one click from any IR page. The tanshin names Director Toshikazu Kokubun (TEL 06-7175-8570). Dedicated and obvious, though the IR menu itself has no contact item, so 4 (the floor; the Sumitomo Bakelite example links an IR page from every IR page). Source document →
R1Earnings materials published in English simultaneously with Japanese5/5
Tanshin and deck in English on TDnet at the same minute as the Japanese in every period read: Q1 FY2026 6 Aug 2026 15:30 (tanshin and supplementary material, both languages), FY2025 14 May 2026 15:30, Q3 13 Feb 2026 15:30, H1 10 Nov 2025 15:30. The scripts are later and scored in S5. So 5. Source document →
R2Median lag in days between Japanese and English statutory publication5/5
English against Japanese: Q1 FY2026 tanshin 6 Aug / 6 Aug = 0; FY2025 tanshin 14 May / 14 May = 0; AGM notice 29 May 08:00 / 29 May 08:00 = 0; CG Report (Japanese 29 Jun and 13 Oct 2026) no English, >90; annual securities report no English, >90. Sorted 0, 0, 0, >90, >90: median 0, so 5. Source document →
R3Timely disclosures published in English5/5
We compared kabutan's TDnet list for Nov 2025 to Oct 2026 and the English Information list. Every timely disclosure has an English version the same day: the impairment and forecast revision (11 May 2026), the Class A preferred share issue to DBJ (21 May; English 16:30 against 15:30), changes in officers (21 May, 24 Jun), treasury-share disposals and completions, controlling-shareholder matters, the Tanabe Pharma Factory acquisition (3 Jul), the payment completion (31 Jul), the Otsuka basic agreement (21 Jan) and every tanshin. Only the 24 Jun 2026 AGM-notice correction, the CG Report and the independent-officer filing have no English, none of R3's kinds. So 5. Source document →
R4English disclosure free of machine-translation accuracy disclaimers5/5
Rendered the English homepage, IR top, Terms of Use and Contact: no machine- or AI-translation notice, no translation widget or pop-up. The documents carry only 'translated from the Japanese original ... the original shall prevail' (R5's). So 5. Source document →
R5English version stated as authoritative, not subordinate to Japanese2/5
'The original shall prevail' is on the AGM notice, the MTP notices and the timely disclosures (e.g. the 15 May 2025 revision). The English tanshin, decks, scripts and integrated report carry no such statement. Disclaimed on some documents, so 2. Source document →
Open a question for the reasoning and the document its score was read from. A zero means no qualifying English materials were located within the stated review scope as of 2026-10-20. Compare this question across companies →
Capital-policy review
Each action is read against the company’s own filings on four checks: was the promise specific, can the steps be traced, were the economics explained, and did it report back against the target. This records the status of selected actions, not an assessment of the company as a whole. How this is scored →
Class A preferred shares to DBJ: up to ¥20bn for growth investment
Equity issuance · In progress · Board resolution 21 May 2026
The first ¥10bn series was paid on 31 July 2026 after shareholder approval on 24 June. The second series of up to ¥10bn is drawn on Towa's notice, and the funds are to be spent from August 2026 to March 2028.
Timeline and sources (2 steps)
- 21 May 2026Board resolved issuance Up to ¥20bn of non-voting Class A preferred shares to the Development Bank of Japan in two series of ¥10bn, with a preferred dividend of 4.4% a year; proceeds for growth investment in Towa's own lines and collaborations from August 2026 to March 2028. Notice of Issuance of Class A Preferred Shares through Third-Party Allotment
- 31 July 2026First series paid Payment of ¥10bn for 10,000 shares completed after approval at the 24 June 2026 AGM; share capital and legal capital surplus reduced by the same amounts. Notice of Completion of Payment for the Issuance of 1st Series Class A Preferred Shares
What management said it would do
Towa resolved on 21 May 2026 to issue up to ¥20bn of non-voting preferred shares to DBJ at a 4.4% preferred dividend, for growth investment from August 2026 to March 2028.
From the company’s own disclosure · Notice of Issuance of Class A Preferred Shares through Third-Party Allotment
What it actually did, and when
The first ¥10bn series was paid on 31 July 2026 after AGM approval; the second series is undrawn.
From the company’s own disclosure · Notice of Completion of Payment for the Issuance of 1st Series Class A Preferred Shares
What it disclosed about the economics
The notice explains why preferred equity was chosen over common shares or debt, but gives no project-level return.
Partly disclosed — a gap remains · Notice of Issuance of Class A Preferred Shares through Third-Party Allotment
What has happened since
The use of proceeds is not due for review until March 2028.
Partly disclosed — a gap remains · Notice of Issuance of Class A Preferred Shares through Third-Party Allotment
The question this leaves open
Investor question: what returns will the ¥20bn earn, and when will the preferred shares be redeemed? IR preparation: publish a use-of-proceeds table and a redemption plan.
Our analysis, not a company statement
Revision of the 6th Medium-term Business Plan PROACTIVE III targets (May 2025) and progress report (May 2026)
Strategy or target reset · In progress · Targets revised 15 May 2025
Towa raised the plan's cumulative operating-profit target from ¥68bn to ¥80bn or more in May 2025. A year later, after a ¥14.7bn impairment of Sunsho Pharmaceutical goodwill, it reported operating profit expected slightly below target (¥78.3bn), ROIC below target (5.3% against 6%) and capital expenditure above it (¥79.3bn against ¥60bn). The final year ends in March 2027.
Timeline and sources (3 steps)
- 15 May 2025Targets revised Cumulative operating profit target raised from ¥68bn to ¥80bn or more; final-year sales ¥300bn, ROIC 6% (7% before goodwill), R&D ¥55bn and capex ¥60bn or more unchanged. Notice of Revisions of Financial Objectives of the 6th Medium-term Business Plan (English published the same day as the Japanese; Japanese version 2025-05-15)
- 11 May 2026Impairment recognised ¥14.7bn goodwill impairment on Sunsho Pharmaceutical; FY2025 net profit forecast cut from ¥17.7bn to ¥5.2bn; effect on plan targets to be disclosed with results. Notice of Recognition of an Impairment Loss, Recognition of a Loss on Valuation of Shares of Subsidiaries and Associates in the Non-consolidated Financial Statements of the Company, and Revisions of Financial Forecasts (English published the same day as the Japanese; Japanese version 2026-05-11)
- 14 May 2026Progress reported Against targets: sales ¥304bn (achieved), cumulative operating profit ¥78.3bn (target ¥80bn), ROIC 5.3% / 5.9% (6% / 7%), R&D ¥55.4bn, capex ¥79.3bn (¥60bn); WACC about 5.5%, cost of equity about 8.5%. FY2025 Supplementary Material of Financial Results (English published the same day as the Japanese; Japanese version 2026-05-14)
What management said it would do
Towa raised its cumulative operating-profit target for FY2024-FY2026 from ¥68bn to ¥80bn or more in May 2025, keeping the ROIC, R&D and capex targets.
From the company’s own disclosure · Notice of Revisions of Financial Objectives of the 6th Medium-term Business Plan (English published the same day as the Japanese; Japanese version 2025-05-15)
What it actually did, and when
In May 2026 it reported progress against each target: sales achieved, operating profit ¥78.3bn, ROIC 5.3%, capex ¥79.3bn, after a ¥14.7bn Sunsho goodwill impairment.
From the company’s own disclosure · Notice of Recognition of an Impairment Loss, Recognition of a Loss on Valuation of Shares of Subsidiaries and Associates in the Non-consolidated Financial Statements of the Company, and Revisions of Financial Forecasts (English published the same day as the Japanese; Japanese version 2026-05-11) · FY2025 Supplementary Material of Financial Results (English published the same day as the Japanese; Japanese version 2026-05-14)
What it disclosed about the economics
It frames returns as ROIC against a WACC of about 5.5% and a cost of equity of about 8.5%, and explains the ROIC shortfall by higher capex, inventory and debt.
From the company’s own disclosure · FY2025 Supplementary Material of Financial Results (English published the same day as the Japanese; Japanese version 2026-05-14)
What has happened since
The final year ends in March 2027; the company already expects operating profit and ROIC below target.
Partly disclosed — a gap remains · FY2025 Supplementary Material of Financial Results (English published the same day as the Japanese; Japanese version 2026-05-14)
The question this leaves open
Investor question: what return will the excess capex earn? IR preparation: give the projects and their expected returns against the stated WACC.
Our analysis, not a company statement
Acquisition of Tanabe Pharma Factory and 35 product approvals from Tanabe Pharma (agreed July 2026)
Acquisition · In progress · Acquisition agreed 3 July 2026
Towa agreed to buy all shares of Tanabe Pharma Factory (two plants) and 17 ingredients / 35 product approvals, with the share transfer planned for the end of November 2026 and the approvals from April 2027, subject to antitrust clearance. The price is not disclosed; negative goodwill is expected.
Timeline and sources (2 steps)
- 3 July 2026Acquisition agreed 22,602 shares (100%) and 35 approvals; acquisition costs not disclosed by agreement, negative goodwill expected; target sales ¥15.8bn and operating profit ¥1.1bn in the year to March 2026; capacity goal of 4-5 billion tablets at the plants by FY2036. Notice of Acquisition of Shares of Tanabe Pharma Factory Co., Ltd. from Tanabe Pharma Corporation (Making it a Wholly Owned Subsidiary) and Transfer of Manufacturing and Marketing Approvals (English published the same day as the Japanese; Japanese version 2026-07-03)
- 8 July 2026 · announced 29 July 2026Briefing material in English The presentation (Japanese 8 July) appeared in English on 29 July, with the target's three-year results and plant output. Acquisition of Shares of Tanabe Pharma Factory Co., Ltd. and Transfer of Manufacturing and Marketing Approvals (presentation) (English published 21 days after the Japanese; Japanese version 2026-07-08)
What management said it would do
Towa agreed to buy all shares of Tanabe Pharma Factory and 35 product approvals from Tanabe Pharma to add domestic supply capacity, closing at the end of November 2026 and from April 2027 for the approvals.
From the company’s own disclosure · Notice of Acquisition of Shares of Tanabe Pharma Factory Co., Ltd. from Tanabe Pharma Corporation (Making it a Wholly Owned Subsidiary) and Transfer of Manufacturing and Marketing Approvals (English published the same day as the Japanese; Japanese version 2026-07-03)
What it actually did, and when
The deal is announced and explained in a briefing; closing has not yet happened, and the English briefing materials came three weeks after the Japanese.
Partly disclosed — a gap remains · Notice of Acquisition of Shares of Tanabe Pharma Factory Co., Ltd. from Tanabe Pharma Corporation (Making it a Wholly Owned Subsidiary) and Transfer of Manufacturing and Marketing Approvals (English published the same day as the Japanese; Japanese version 2026-07-03) · Acquisition of Shares of Tanabe Pharma Factory Co., Ltd. and Transfer of Manufacturing and Marketing Approvals (presentation) (English published 21 days after the Japanese; Japanese version 2026-07-08) · Briefing Script and Q&A Summary of briefing on the Acquisition of Shares of Tanabe Pharma Factory Co., Ltd. and Transfer of Manufacturing and Marketing Approvals (English published 20 days after the Japanese; Japanese version 2026-07-29)
What it disclosed about the economics
The price is not disclosed by agreement; the notice gives the target's sales of ¥15.8bn, operating profit of ¥1.1bn and net assets of ¥31.7bn, and expects negative goodwill.
Partly disclosed — a gap remains · Notice of Acquisition of Shares of Tanabe Pharma Factory Co., Ltd. from Tanabe Pharma Corporation (Making it a Wholly Owned Subsidiary) and Transfer of Manufacturing and Marketing Approvals (English published the same day as the Japanese; Japanese version 2026-07-03)
What has happened since
The outcome is not due; the company has promised to disclose the negative goodwill and the forecast effect.
Partly disclosed — a gap remains · Notice of Acquisition of Shares of Tanabe Pharma Factory Co., Ltd. from Tanabe Pharma Corporation (Making it a Wholly Owned Subsidiary) and Transfer of Manufacturing and Marketing Approvals (English published the same day as the Japanese; Japanese version 2026-07-03)
The question this leaves open
Investor question: what did Towa pay and what will the plants cost to expand? IR preparation: disclose the negative goodwill on closing and the capex plan to 2036.
Our analysis, not a company statement
Balance sheet and capital-policy indicators
A source-backed first-pass capital-efficiency, balance-sheet and governance reading, separate from the accountability score.
Cash use and returns
FY2025 operating cash flow was ¥30.4bn against ¥25.7bn of investing outflow; profit fell to ¥5.3bn after an impairment.
Capital structure
Long-term borrowings were ¥183.3bn against net assets of ¥178.1bn and a 37.5% equity ratio; the ¥10bn preferred issue adds equity.
Governance of capital decisions
The 6th plan targets ROIC of 6% or more (7% before goodwill); FY2025 ROE was 3.0%.
Preliminary and not scored: a selected-source reading, reviewed 20 October 2026. Surplus cash, leases, maturities, project returns, cost of capital, committed spend and peer comparability are not fully assessed; none enters the accountability score. Figures are the company’s own reported numbers; a large cash balance is not called excess without a defensible operating reserve and investment plan. Every company with a balance-sheet reading →
Changes to this record
- Research error 23 October 2026 · G5: 5 → 4. Every proposal is in the English notice, but the voting website shareholders use (Mitsubishi UFJ Trust and Banking) is in Japanese only.
Every change is labelled as a research error, new evidence supplied, improved disclosure or a rule change, with its date and the previous score. Change log →
Scores assess how English information is published, not the quality of the business or its investment value. To report an error or a document we missed, see how to contact us.